[Unwanted bone changes in systemic treatment with synthetic retinoids]

Area of Science:

• Dermatology and Pharmacology
• Skeletal Biology

Context:

• Oral retinoids are widely used for dermatological conditions.
• Synthetic retinoids, including 13-cis-retinoic acid (isotretinoin) and etretinate, are significant therapeutic agents.
• Bone changes have been observed with these treatments.

Purpose:

• To review and update the understanding of bone changes associated with oral isotretinoin and etretinate.
• To analyze clinical studies on retinoid-induced skeletal toxicity.
• To assess the risk-benefit ratio of long-term retinoid therapy.

Summary:

• 13-cis-retinoic acid (isotretinoin) is definitively linked to bone toxicity.
• Etretinate may cause bone changes, but a longer latency period requires further investigation.
• Clinical data on skeletal toxicity are crucial for risk-benefit assessments.

Impact:

• Informs clinical decision-making for patients requiring long-term retinoid treatment.
• Highlights the importance of monitoring skeletal health during retinoid therapy.
• Contributes to a better understanding of the long-term effects of synthetic retinoids.